Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Filing Type: Form 8-K (Current Report)
Report Date: February 26, 2026
Event: Entry into a Material Definitive Agreement for technology transfer.
Key Financial Metrics and Transaction Details
This filing reports a specific transaction rather than periodic financial performance. Key metrics related to the transaction include:
- Transaction Value: $6.93 million.
- Payment Method: Issuance of 12,600,000 restricted shares of common stock.
- Issuance Price: $0.55 per share.
- Asset Acquired: Ownership of an invention patent for "Prinsepia Utilis Esterol Sublingual Tablets and Method for Its Preparation."
- Counterparty: Xiaoyan Zhang (Transferor), a non-U.S. person.
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Transaction Structure
The Company, through its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd., entered into a Technology Transfer Agreement. The primary material change is the acquisition of intellectual property rights in exchange for equity. The Transferor is obligated to provide technical services, including product R&D and registration application support.
Guidance, Risks, and Regulatory Status
- Regulatory Exemption: The 12.6 million shares are unregistered and issued in reliance on Regulation S of the Securities Act, as the transaction was negotiated and consummated outside the United States with a non-U.S. person.
- Confidentiality: Portions of the Technology Transfer Agreement exhibit were omitted from the public filing to protect confidential information.
- Outlook: The filing does not contain forward-looking guidance or management commentary regarding future financial performance.
Investor Verification Checklist
- Verify the valuation of the "Prinsepia Utilis Esterol Sublingual Tablets" patent against the $6.93 million transaction price.
- Confirm the dilution impact of the 12,600,000 new restricted shares on existing shareholders.
- Review the full Technology Transfer Agreement (Exhibit 10.1) to understand the specific milestones and obligations for the technical services provided by the Transferor.
- Assess the regulatory status of the sublingual tablet product in relevant markets.